Business Description
AstraZeneca PLC
NAICS : 325412
ISIN : ARDEUT112489
Share Class Description:
BUE:AZN: CedearDescription
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.85 | |||||
| Debt-to-EBITDA | 2.36 | |||||
| Interest Coverage | 5.92 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.78 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 14 | |||||
| 3-Year EPS without NRI Growth Rate | 37.2 | |||||
| 3-Year FCF Growth Rate | 38.8 | |||||
| 3-Year Book Growth Rate | 31.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 33.24 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.57 | |||||
| 9-Day RSI | 25.92 | |||||
| 14-Day RSI | 27.13 | |||||
| 6-1 Month Momentum % | 22056.18 | |||||
| 12-1 Month Momentum % | 22056.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.89 | |||||
| Quick Ratio | 0.69 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 221.96 | |||||
| Days Sales Outstanding | 78.67 | |||||
| Days Payable | 694.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.57 | |||||
| Dividend Payout Ratio | 0.17 | |||||
| 3-Year Dividend Growth Rate | 2.9 | |||||
| Forward Dividend Yield % | 1.57 | |||||
| 5-Year Yield-on-Cost % | 1.67 | |||||
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 2.13 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.08 | |||||
| Operating Margin % | 19.96 | |||||
| Net Margin % | 13.1 | |||||
| FCF Margin % | 13.73 | |||||
| ROE % | 16.87 | |||||
| ROA % | 6.43 | |||||
| ROIC % | 9.53 | |||||
| 3-Year ROIIC % | 11.23 | |||||
| ROC (Joel Greenblatt) % | 91.61 | |||||
| ROCE % | 13.14 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.69 | |||||
| Forward PE Ratio | 4.47 | |||||
| PE Ratio without NRI | 30.88 | |||||
| Shiller PE Ratio | 57.02 | |||||
| Price-to-Owner-Earnings | 23.44 | |||||
| PEG Ratio | 4.83 | |||||
| PS Ratio | 4.43 | |||||
| PB Ratio | 5.51 | |||||
| Price-to-Free-Cash-Flow | 31.17 | |||||
| Price-to-Operating-Cash-Flow | 19.65 | |||||
| EV-to-EBIT | 25.74 | |||||
| EV-to-Forward-EBIT | 15.55 | |||||
| EV-to-EBITDA | 17.17 | |||||
| EV-to-Forward-EBITDA | 12.71 | |||||
| EV-to-Revenue | 4.92 | |||||
| EV-to-Forward-Revenue | 4.52 | |||||
| EV-to-FCF | 34.64 | |||||
| Price-to-Projected-FCF | 2.64 | |||||
| Price-to-DCF (Earnings Based) | 0.41 | |||||
| Price-to-DCF (FCF Based) | 1.05 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.33 | |||||
| Earnings Yield (Greenblatt) % | 3.89 | |||||
| FCF Yield % | 3.23 | |||||
| Forward Rate of Return (Yacktman) % | 11.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AstraZeneca PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 30,630,326.031 | ||
| EPS (TTM) (ARS) | 2821.696 | ||
| Beta | 0 | ||
| Volatility % | 22661.47 | ||
| 14-Day RSI | 27.13 | ||
| 14-Day ATR (ARS) | 969.585815 | ||
| 20-Day SMA (ARS) | 44827.5 | ||
| 12-1 Month Momentum % | 22056.18 | ||
| 52-Week Range (ARS) | 214.5 - 58050 | ||
| Shares Outstanding (Mil) | 1,550.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AstraZeneca PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AstraZeneca PLC Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
AstraZeneca PLC Frequently Asked Questions
What is AstraZeneca PLC(BUE:AZN)'s stock price today?
The current price of BUE:AZN is ARS42025.00. The 52 week high of BUE:AZN is ARS58050.00 and 52 week low is ARS214.50.
When is next earnings date of AstraZeneca PLC(BUE:AZN)?
The next earnings date of AstraZeneca PLC(BUE:AZN) is 2024-11-12.
Does AstraZeneca PLC(BUE:AZN) pay dividends? If so, how much?
The Dividend Yield %  of AstraZeneca PLC(BUE:AZN) is 1.57% (As of Today), Highest Dividend Payout Ratio of AstraZeneca PLC(BUE:AZN) was 35.15. The lowest was 0.17. And the median was 1.8. The  Forward Dividend Yield % of AstraZeneca PLC(BUE:AZN) is 1.57%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers